Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day


Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in a fireside chat at the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day on Monday, November 18, 2019 at 9:00 a.m. ET in New York, NY.

A live audio webcast and archive of the presentation will be available at http://investor.dermira.com.

About Dermira

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products. The company's approved treatment, QBREXZA® (glycopyrronium) cloth, is indicated for pediatric and adult patients (ages 9 and older) with primary axillary hyperhidrosis (excessive underarm sweating). Please see the QBREXZA prescribing information. Dermira is evaluating lebrikizumab in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis (a severe form of eczema) and has early-stage research and development programs in other areas of dermatology. Dermira is headquartered in Menlo Park, Calif. For more information, please visit http://www.dermira.com. Follow Dermira on Twitter, LinkedIn and Instagram.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com), LinkedIn page (https://www.linkedin.com/company/dermira-inc-), corporate Instagram account (https://www.instagram.com/dermira_inc/) and corporate Twitter account (@DermiraInc) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira's website, LinkedIn page, Instagram and Twitter accounts in addition to following its SEC filings, news releases, public conference calls and webcasts.


These press releases may also interest you

at 03:10
AgraFlora Organics International Inc. ("AgraFlora" or the "Company") , a growth oriented and diversified international cannabis company, is pleased to announce that the Company's wholly owned subsidiary, Farmako GmbH ("Farmako") has secured a...

at 03:00
Korea Centers for Disease Control & Prevention notified Seegene Inc. (096530.KQ) that Korea Ministry of Food and Drug Safety (MFDS; Former KFDA) approved its novel coronavirus (COIVD-19) Real-time PCR assay for the Emergency Use, following the recent...

at 03:00
"A smile says a lot about you. When you smile, you're saying hello to the world," says NJ Top Dentist Dr. Ivan Stein of Northfield Dental Group. At Northfield Dental Group, they do their best to give patients the smile they want. Their goal is for...

at 03:00
MMI SpA, an Italian company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced today the appointment of Ryan Rhodes to the position of Global Chief Commercial Officer. Mr. Rhodes...

at 03:00
R3 Medical Training is now offering $500 for its Comprehensive two day stem cell training course. The discount applies to those registering online for the course and the code to use for the discount is R3FIVE. The next course is March 13-14th at the...

at 03:00
Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, has repurchased 238,303 of its own shares in the period from 10 February 2020 up to and including 14 February 2020 at an average price of ?116.31. This is in...



News published on 11 november 2019 at 16:15 and distributed by: